Field Notes and the Hidden Failure Modes
I once stood in a small pathology lab in Jakarta in 2019 watching a team struggle with tissue mounting—30% of their slides failed quality control; what change would cut that failure rate in half? I work with spatialomics every week, and I use the term spatial transcriptomics deliberately: it ties expression to position, not just numbers on a spreadsheet. I’ve run RNA-seq and barcoding workflows on fresh-frozen breast biopsies and seen how small habits—rough handling, slow freezing—crush spatial resolution and skew the transcriptome profile. That design genuinely frustrated me then; I fixed one step and the next step broke (classic trade-off).
Let me be blunt: most teams patch results with heavier sequencing or repeated runs. Those are expensive band-aids. I remember ordering a 10x Visium kit for a university project in November 2019 and later finding that inconsistent permeabilization gave misleading in situ hybridization signals. The real pain point is workflow drift—people switch vendors, change incubation times, and assume everything else is constant. I track these changes in logs; they matter. We need steps that protect spatial context first, then signal fidelity. Short, direct changes. No fluff. Moving on—
Technical Look Ahead: Better Metrics, Better Choices
Now I shift gears: compare concrete metrics across protocols—mapping rate, spot-level sensitivity, and spatial resolution. I plot these for three common pipelines and the differences are clear: one protocol gives higher mapping rate, another preserves morphology better, and the third is cheaper but noisier. When I evaluate, I measure mapping rate (%) and mean unique molecular identifiers (UMIs) per spot, and I also inspect tissue morphology under 20x quickly. That gives real, actionable trade-offs. For example, a 45% mapping rate with clean morphology may beat a 70% mapping rate where cell boundaries are lost. I learned this at a trial in Bandung—results surprised everyone. Short note: barcoding chemistry matters. Also—sample handling before barcoding is crucial.
What’s Next?
Looking forward, I expect integrated QC dashboards and clearer SOPs to reduce drift. We will see better harmonization between imaging and sequencing data—bridging in situ hybridization signals with transcript counts. I already test multimodal runs that align fluorescent markers with transcript maps; early results cut ambiguous calls by about 15%. We must ask for reproducible metrics from vendors and insist on raw data access. I keep recommending three simple things: track pre-analytic handling, record permeabilization times, and run a morphology check before sequencing. That’s practical. It works.
Three Metrics You Can Use Today
As someone with over 15 years advising labs in molecular diagnostics, I give this checklist. First: mapping rate (%) — your baseline for alignment success. Second: UMIs per spot — tells you signal depth at spatial scale. Third: morphology score (simple 1–5) — I score tissue sections before sequencing; if it’s ≤2 I stop and re-process. Use these three to compare pipelines quickly. I’ve applied them on human lung and liver studies; they reduced repeat runs by nearly 25% in my practice. Try them. Also, a small aside—talk to technicians. They know where things break, fast.
I’ll close with a practical promise: focus on reproducible steps, not just higher read depth. For more resources and tools I trust, see stomics.
